Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512100-19-00

Enrollment

Registered

2024-10-14

Start date

2023-05-15

Completion date

2025-01-15

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild autonomous cortisol secretion in patients with adrenal adenoma

Brief summary

Hepatic lipid content (HCL) assessed by 1H magnetic resonance spectroscopy

Detailed description

insulin secretion and sensitivity based on validated indices (HOMA_IR, CLIX) • subcutaneous and visceral fat mass, body composition • Systolic and diastolic heart function, epicardial and pericardial fat mass • ectopic lipid deposition in the skeletal muscle and the myocardium • standardized blood pressure measurements (blood pressure for 24h hours and Schellong tests) • parameters of systemic inflammation (CRP, Il-6, PAI-1, TNF-alpha, homocysteine, leucocytes, monocytes)

Interventions

DRUGMetyrapone HRA 250mg soft capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Hepatic lipid content (HCL) assessed by 1H magnetic resonance spectroscopy	—

Secondary

Measure	Time frame
insulin secretion and sensitivity based on validated indices (HOMA_IR, CLIX) • subcutaneous and visceral fat mass, body composition • Systolic and diastolic heart function, epicardial and pericardial fat mass • ectopic lipid deposition in the skeletal muscle and the myocardium • standardized blood pressure measurements (blood pressure for 24h hours and Schellong tests) • parameters of systemic inflammation (CRP, Il-6, PAI-1, TNF-alpha, homocysteine, leucocytes, monocytes)	—

Measure

Time frame

—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026